RESUMO
This study aimed to test the effects of xuezhikang, a cholestin extract that contains statin-like components, on arterial stiffness in patients with essential hypertension. One hundred hypertensive patients from the Chinese PLA General Hospital were randomly allocated to receive xuezhikang (1200 mg/day, orally) or placebo (same capsules containing only pharmaceutical excipients). Physical examination outcomes, lipid profile, high sensitivity C-reactive protein (hs-CRP) levels, matrix metalloproteinases-9 (MMP-9) levels, and arterial outcomes, including stiffness parameter (ß), pressure-strain elasticity modulus (Ep), arterial compliance (AC), augmentation index (AI), and one-point pulse wave velocity (PWVß) were obtained at baseline and after 6 months of the intervention. Xuezhikang significantly reduced ß (8.4±3.1 vs 6.8±2.1, P=0.007), Ep (122.8±43.9 vs 100.7±33.2, P=0.009), PWVß (6.7±1.2 vs 6.1±1.0, P=0.013), low-density lipoprotein cholesterol (3.4±0.6 vs 2.9±0.5, P=0.001), hs-CRP [2.1 (0.4-10.0) vs 1.4 (0.3-4.1), P=0.020], and MMP-9 (17.2±2.4 vs 12.7±3.8, P <0.001) compared to baseline. The placebo had no effect on these parameters. The changes of PWVß in the xuezhikang group was significantly associated with the changes of hs-CRP and MMP-9 (r=0.144, P=0.043; r=0.278, P=0.030, respectively) but not with lipid profile changes. Our research showed xuezhikang can improve the parameters of arterial stiffness in hypertensive patients, and its effect was independent of lipid lowering.
Assuntos
Medicamentos de Ervas Chinesas/uso terapêutico , Hipertensão Essencial/tratamento farmacológico , Rigidez Vascular/efeitos dos fármacos , Medicamentos de Ervas Chinesas/efeitos adversos , Hipertensão Essencial/sangue , Hipertensão Essencial/fisiopatologia , Feminino , Humanos , Lipídeos/sangue , Masculino , Pessoa de Meia-Idade , Análise de Onda de Pulso , Rigidez Vascular/fisiologiaRESUMO
This study aimed to test the effects of xuezhikang, a cholestin extract that contains statin-like components, on arterial stiffness in patients with essential hypertension. One hundred hypertensive patients from the Chinese PLA General Hospital were randomly allocated to receive xuezhikang (1200 mg/day, orally) or placebo (same capsules containing only pharmaceutical excipients). Physical examination outcomes, lipid profile, high sensitivity C-reactive protein (hs-CRP) levels, matrix metalloproteinases-9 (MMP-9) levels, and arterial outcomes, including stiffness parameter (β), pressure-strain elasticity modulus (Ep), arterial compliance (AC), augmentation index (AI), and one-point pulse wave velocity (PWVβ) were obtained at baseline and after 6 months of the intervention. Xuezhikang significantly reduced β (8.4±3.1 vs 6.8±2.1, P=0.007), Ep (122.8±43.9 vs 100.7±33.2, P=0.009), PWVβ (6.7±1.2 vs 6.1±1.0, P=0.013), low-density lipoprotein cholesterol (3.4±0.6 vs 2.9±0.5, P=0.001), hs-CRP [2.1 (0.4-10.0) vs 1.4 (0.3-4.1), P=0.020], and MMP-9 (17.2±2.4 vs 12.7±3.8, P <0.001) compared to baseline. The placebo had no effect on these parameters. The changes of PWVβ in the xuezhikang group was significantly associated with the changes of hs-CRP and MMP-9 (r=0.144, P=0.043; r=0.278, P=0.030, respectively) but not with lipid profile changes. Our research showed xuezhikang can improve the parameters of arterial stiffness in hypertensive patients, and its effect was independent of lipid lowering.
Assuntos
Humanos , Masculino , Feminino , Pessoa de Meia-Idade , Medicamentos de Ervas Chinesas/uso terapêutico , Hipertensão Essencial/tratamento farmacológico , Rigidez Vascular/efeitos dos fármacos , Medicamentos de Ervas Chinesas/efeitos adversos , Hipertensão Essencial/sangue , Hipertensão Essencial/fisiopatologia , Lipídeos/sangue , Análise de Onda de Pulso , Rigidez Vascular/fisiologiaRESUMO
The effects of interleukin-10 (IL-10) and glucose on mRNA and protein expression of osteoprotegerin (OPG), and its ligand, receptor activator of nuclear factor-κB ligand (RANKL), were investigated in human periodontal ligament fibroblasts (HPDLFs). Primary HPDLFs were treated with different concentrations of IL-10 (0, 1, 10, 25, 50, and 100 ng/mL) or glucose (0, 5.5, 10, 20, 30, and 40 mmol/L). Changes in mRNA and protein expression were examined using the reverse-transcription polymerase chain reaction (RT-PCR) and Western blot analysis, respectively. After IL-10 treatment, mRNA and protein levels of OPG were increased, while mRNA and protein levels of RANKL were decreased (P<0.05), both in a concentration-dependent manner. Glucose stimulation had the opposite concentration-dependent effect to that of IL-10 on OPG and RANKL expression. IL-10 upregulated OPG expression and downregulated RANKL expression, whereas high glucose upregulated RANKL and downregulated OPG in HDPLFs. Abnormal levels of IL-10 and glucose may contribute to the pathogenesis of periodontal disease.
Assuntos
Fibroblastos/efeitos dos fármacos , Glucose/farmacologia , Interleucina-10/farmacologia , Osteoprotegerina/metabolismo , Ligamento Periodontal/efeitos dos fármacos , Ligante RANK/metabolismo , Análise de Variância , Western Blotting , Células Cultivadas , Regulação para Baixo , Fibroblastos/metabolismo , Humanos , Ligamento Periodontal/citologia , RNA Mensageiro/análise , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Fatores de Tempo , Regulação para CimaRESUMO
The effects of interleukin-10 (IL-10) and glucose on mRNA and protein expression of osteoprotegerin (OPG), and its ligand, receptor activator of nuclear factor-κB ligand (RANKL), were investigated in human periodontal ligament fibroblasts (HPDLFs). Primary HPDLFs were treated with different concentrations of IL-10 (0, 1, 10, 25, 50, and 100 ng/mL) or glucose (0, 5.5, 10, 20, 30, and 40 mmol/L). Changes in mRNA and protein expression were examined using the reverse-transcription polymerase chain reaction (RT-PCR) and Western blot analysis, respectively. After IL-10 treatment, mRNA and protein levels of OPG were increased, while mRNA and protein levels of RANKL were decreased (P<0.05), both in a concentration-dependent manner. Glucose stimulation had the opposite concentration-dependent effect to that of IL-10 on OPG and RANKL expression. IL-10 upregulated OPG expression and downregulated RANKL expression, whereas high glucose upregulated RANKL and downregulated OPG in HDPLFs. Abnormal levels of IL-10 and glucose may contribute to the pathogenesis of periodontal disease.
Assuntos
Humanos , Ligamento Periodontal/efeitos dos fármacos , Interleucina-10/farmacologia , Ligante RANK/metabolismo , Osteoprotegerina/metabolismo , Fibroblastos/efeitos dos fármacos , Glucose/farmacologia , Ligamento Periodontal/citologia , Fatores de Tempo , RNA Mensageiro/análise , Regulação para Baixo , Regulação para Cima , Células Cultivadas , Western Blotting , Análise de Variância , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Fibroblastos/metabolismoRESUMO
It has been well established that high-sensitivity cardiac troponin T (hs-TnT) is a specific and highly sensitive marker in acute coronary syndromes. On the other hand, studies on serum concentrations of hs-TnT in patients with hypertension in the absence of significant coronary stenosis are limited. Therefore, we hypothesized that hs-TnT levels are related to left ventricular (LV) remodeling and performance in hypertension. We included 537 hemodynamically stable hypertensive subjects, 247 males aged 60.7 ± 11.1 years, and 100 normotensive subjects of similar age and gender. Clinical examination, clinical assessment and laboratory assays were performed for all hypertensive and normotensive subjects. The detectable rate (>0.003 ng/mL) and elevated rate (>0.013 ng/mL) of hs-TnT were higher in hypertensive subjects than those in normotensive subjects. hs-TnT level gradually increased in hypertensive subjects with LV normal geometry, concentric remodeling, concentric hypertrophy and eccentric hypertrophy. hs-TnT was independently related to age, gender, hypertension, fasting blood glucose, renal function, and LV hypertrophy, and diastolic function on multiple analysis during the whole participation. An increase in hs-TnT levels could be a reliable biomarker of cardiac remodeling and function in hypertension, as an indicator of subclinical ongoing cardiomyocyte injury.